Dr. Reddy’s launched Sapropterin Dihydrochloride Powder

Tuesday April 13, 2021 at 11:30 am

Hyderabad, India and Princeton, NJ, USA. April 7, 2021 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DR REDDY, NYSE: RDY, NSEIFSC: DR REDDY along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Sapropterin Dihydrochloride Powder for Oral Solution, 100mg, a therapeutic equivalent generic version of Kuvan® (sapropterin dihydrochloride) Powder for Oral Solution, 100 mg, USP, approved by the U.S. Food and Drug Administration (USFDA). “We are pleased to launch this generic version of Sapropterin Dihydrochloride Powder for Oral Solution, illustrating our continued commitment to bringing affordable generic medicines to market for patients,” says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories. “At the same time, this product demonstrates that we are actively expanding the breadth of our portfolio with a treatment for a rare disease.” Dr. Reddy’s Sapropterin Dihydrochloride Powder for Oral Solution is available in 100 mg unit dose packets in a 30 count carton.

Releted Blog